Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress

This article was originally published in The Tan Sheet

Executive Summary

BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.

You may also be interested in...



In Brief: Hormel Buys CytoSport, FDA Warns On Drug Claims, Mira Health Consent Decree

Hormel flexes Muscle Milk for protein; Hangover prevention claims are disease claims; Mira Health cannot resume supplement production without FDA permission; Batch production records require details; Laclede needs drug approval for vaginal products and U.S. & Korea ink organic equivalency agreement.

In Brief: Hormel Buys CytoSport, FDA Warns On Drug Claims, Mira Health Consent Decree

Hormel flexes Muscle Milk for protein; Hangover prevention claims are disease claims; Mira Health cannot resume supplement production without FDA permission; Batch production records require details; Laclede needs drug approval for vaginal products and U.S. & Korea ink organic equivalency agreement.

China Tightens Infant Formula Industry Oversight, Levels Playing Field

China steps up oversight of pricing and compliance in the infant formula industry, imposing requirements similar to those for drug manufacturers. To tighten supervision, CFDA publishes new rules on manufacturing and marketing that raise standards and prohibit promotion of formula to medical institutions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel